Adbiotech Co Ltd Ordinary Shares 179530
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 2,430.00–2,495.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 2,410.00 / KRW 2,530.00
- Market Cap
- KRW 22.76 Bil
- Volume/Avg
- 8,879 / 24,955
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.14
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adbiotech Co Ltd is a life science company. It develops a vaccine and antibiotic-friendly substances such as IgY, Immunoglobulin in Yolk for human, animal and fish oral antibody products, and functional cosmetics and food additives. The company aim to develop Helico IgY, Cholesterol IgY, and Ulcerative Colitis natural product medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 62
- Website
- http://www.adbiotech.com
Valuation
|
Metric
|
179530
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.73 |
Price/Sales | 2.14 |
Price/Cash Flow | — |
Price/Earnings
179530
Financial Strength
|
Metric
|
179530
|
|---|---|
Quick Ratio | 0.85 |
Current Ratio | 1.03 |
Interest Coverage | −12.15 |
Quick Ratio
179530
Profitability
|
Metric
|
179530
|
|---|---|
Return on Assets (Normalized) | −17.45% |
Return on Equity (Normalized) | −35.32% |
Return on Invested Capital (Normalized) | −18.40% |
Return on Assets
179530
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zwgdphsh | Tghl | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tgrbcnhp | Bhfdzg | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wrqyrjf | Jchpbg | $99.5 Bil | |
MRNA
| Moderna Inc | Smtbwqnzk | Sqt | $38.8 Bil | |
ARGX
| argenx SE ADR | Plrtpxn | Jnzs | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Rhvssxrf | Fbyw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gwcsqmlb | Lsnbrt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rwnlplrd | Zkbvy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cxhhdvznsq | Gvjmjh | $12.5 Bil | |
INCY
| Incyte Corp | Kznvsmxs | Qdykb | $11.6 Bil |